Altimmune ALT EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Altimmune's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Altimmune's EPS (diluted)?
- Altimmune (ALT) reported EPS (diluted) of -$0.18 in Q1 2026.
- How has Altimmune's EPS (diluted) changed year-over-year?
- Altimmune's EPS (diluted) increased by 30.8% year-over-year, from -$0.26 to -$0.18.
- What is the long-term trend for Altimmune's EPS (diluted)?
- Over 4 years (2021 to 2025), Altimmune's EPS (diluted) has grown at a -19.2% compound annual growth rate (CAGR), from -$2.35 to -$1.00.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.